Offerings to Meet the Needs of Every PGx Program

Based on client feedback, AccessDx Laboratory is now offering multiple PGx testing options.

The AccessDx PGx Profile includes:

    • Drug-gene interactions across 16+ therapeutic areas
    • Easy-to-understand, actionable, evidence-based PGx insights from 19,000+ publications and product inserts
    • Common and rare ethno-specific variations – including many targets not routinely detected by other US laboratories
    • Two panel options to meet your clinical needs:

Comprehensive Panel

Includes 37+ high-evidence and emerging-evidence genes, with four add-on genes available (APOE and HLA risk alleles)

Focused Panel

Includes 20 high-evidence genes with actionable guidance, including HLA risk alleles

Learn More about the PGx Profile

Single Gene Testing for DPYD:

    • Aligns with recent FDA black box warning updates and NCCN recommendations that explicitly recommend pre-treatment DPYD testing
    • Enables oncology care teams to identify patients with DPD deficiency prior to treatment with capecitabine (Xeloda®) or fluorouracil/5-FU to reduce the risk of serious adverse reactions
Learn More about DPYD Testing

How is AccessDx PGx testing different from other PGx tests on the market?

    • Tests are developed and validated by a team of experts in pharmacogenomics, biomedical informatics, molecular and cellular biology, cancer biology, and genetics
    • Our clinical decision support tool, YouScript®, has demonstrated proven care improvements and cost reductions in 15+ published studies
    • Results and insights auto-populate in clinical decision support tools like YouScript and via direct integrations with all major EHRs

Our PGxperts™ are an extension of your precision medicine team - we're here when you need us for education, results reviews, clinical team training, program expansion, and support.

Contact us to Learn More

Start Testing

Why work with AccessDx Laboratory?

We’re your collaborative partner:

    • Our team is an extension of your precision medicine program – we provide education and training, benchmarking, program marketing, and ongoing program support

We’re the experts:

    • 400+ peer-reviewed papers, abstracts, and articles
    • 300+ invited lectures across 5 continents
    • Participates or are in leadership positions in PharmVar, STRIPE Steering Committee, ClinGen, and ACS-CAN PGx Working Groups
    • Combined 250+ years of experience in precision medicine

Frequently Asked Questions

Are the results of your test integrated in clinical decision support tools?

Yes, the AccessDx PGx Profile and single-gene testing results auto-populate into our clinical decision support tools, which can be accessed via the AccessDx laboratory portal or through several EMRs via direct integrations with the 2bPrecise® platform or YouScript® clinical decision support software.

Are these PGx test options covered by insurance?

PGx testing is typically covered when proper medical necessity has been documented based on the patient’s condition and/or prescribed medications. This coverage continues to evolve. As with any other test or service, reimbursement is subject to individual health plan policies, including deductible and copay amounts for which the patient may be responsible.

The Centers for Medicare & Medicaid Services (CMS) covers PGx, subject to policy and medical necessity for testing, as outlined in its Local Coverage Determination (LCD) L39063, effective 12/12/2021.

How quickly can I get started?

Get started with PGx testing with AccessDx Laboratory in 48 hours by registering below.

Contact us to get started

To learn more and begin ordering tests from AccessDx Laboratory, please fill out the following form.

Name
What are you interested in?
By filling out this form, you agree to receive communications like newsletters, marketing or promotional materials, and other information from AccessDx Laboratory and our parent company, Aranscia®. You may opt-out of receiving communications from us by using the unsubscribe link at the bottom of all emails or contacting us directly.